Listen to Avalere Health Essential Voice podcasts. Twenty years ago, we set out to be the essential voice in improving healthcare. Rest your eyes or use your commute time to hear our experts discuss the hot topics that you need to track.
In our patient engagement series, hear Alex Goolsby discuss opportunities for provider organizations, health plans, patient advocacy groups, and drug and device manufacturers to engage patients through education and collaboration to improve healthcare.
In recent years, stakeholders have increasingly become aware of the potential opportunities surrounding incorporation of the patient perspective into early stages of drug development. Listen to Debleena Sengupta discuss how patient input is evaluated and incorporated into the FDA's decision-making process.
To what extent do patients currently have access to their own data in their providers’ electronic health records, and what does the future hold for consumer access to their digital health data? Listen to Avalere's Josh Seidman share how far we’ve come with providing patients access to their health data, where there is still room for improvement, and what patients can expect to see in the future.
While Medicare Access and CHIP Reauthorization Act or MACRA seeks to stabilize Medicare and assure physicians a predictable stream of revenue given a schedule of expected physician payment updates, how can providers leverage MACRA to improve quality of care? Listen in as Kristi Mitchell suggests how providers can use MACRA as a springboard to develop and implement relevant quality measures to close the current measurement gaps across disease conditions and care settings.
The ACA is built on a foundation of improving the quality of care for all patients and includes a number of provisions to help consumers make decisions about where to receive their care as well as how to increase the transparency of services through value-based purchasing efforts and private sector programs. Listen in as Nelly Ganesan discusses the trend of using value-based systems in quality reporting programs which will require physicians to focus on outcomes versus processes.
When life sciences companies consider whether to allow compassionate use—access to unapproved investigational treatments outside of clinical trials—there are no easy answers. Brenda Huneycutt gleans insight from Arthur Caplan, PhD, and Alison Bateman-House, PhD, from the New York University Langone Medical Center Division of Medical Ethics on some of the many questions that life sciences companies should ask themselves before implementing a compassionate use policy.
As risk shifts, so too does the responsibility for delivering high-quality outcomes at lower costs. In this podcast, listen in as Sally Rodriguez discusses the impact of this shift and the momentum surrounding delivery models. Sally explores what’s ahead for this changing landscape and the opportunities that await.
Avalere Health and The SCAN Foundation partner to understand the interplay between medical and non-medical issues. Listen to Avalere’s Sally Rodriguez detail September’s white paper release.
The long waiting game for ACO stakeholders is no more after CMS finally released their much-anticipated proposed ACOs Rule 2.0 on December 1, 2014. Listen to Josh Seidman dive into the most recent CMS Medicare Shared Savings Program (MSSP) Rule.
Listen to Avalere's Debbie Lucas explain the complex world of quality measurement.
As stakeholders across the healthcare spectrum continue to wait for CMS’ ACOs Rule 2.0, Avalere’s Josh Seidman takes a crack at pinpointing the much anticipated ACO policy changes.
With something as complex and as political as shared savings models in healthcare, there will always be push-back. But according to Avalere’s Josh Seidman, now is a unique opportunity for Accountable Care Organizations (ACOs) to finally succeed. Josh explains that the current healthcare infrastructure makes ACOs attainable thanks to recent changes, including increased electronic health record use, more provider comfort with comparative performance reporting, enhanced centrality of patient engagement and new incentives that reward accountability and value.
Even during these gridlocked times in Congress, certain healthcare initiatives are getting through the cracks; one of these such initiatives is 21st Century Cures.
Listen to Debbie Lucas discuss how quality measurement can lead to improvements in the quality of care and the impact on providers.
The use of quality and performance measures in public reporting, value-based purchasing, and alternative payment models is altering clinical practice by providing incentives to improve quality measures performance and provide high-value care. Debbie Lucas helps many stakeholders seek to understand these measures, assess their business impacts, and use the information to guide decision-making.
Meet Kathy Hughes who leads our Molecular Diagnostics team and has successfully advised device, diagnostics and pharmaceutical companies on optimal market access strategies for over a decade. Kathy addresses key evidentiary developments in the diagnostics space, and what she sees as the future of this evolving field.
A June 2014 Avalere survey asserts that while 90% of pharmaceutical and biotech manufacturers are offering cost-sharing assistance to exchange patients, the type of support, generosity and program structure vary widely.
In this podcast, Matt Eyles, Executive Vice President of Health Plans and Providers, gives a short preview of his upcoming MHPA presentation, Medicaid Premium Assistance Programs: Opportunities and Challenges for States and Plans.